Literature DB >> 9264285

Synthetic peptide ELISAs for detection of and discrimination between group M and group O HIV type 1 infection.

P Mauclère1, F Damond, C Apetrei, I Loussert-Ajaka, S Souquière, L Buzelay, P Dalbon, M Jolivet, M Mony Lobe, F Brun-Vézinet, F Simon, F Barin.   

Abstract

We developed and evaluated two peptide-based immunoassays to confirm and discriminate between group M and group O HIV-1 infection. These assays are based on in vitro competition for antibody binding between M and O peptides. The first EIA is based on competition between group M and group O gp41 immunodominant domains and the second on competition between group O and group M V3 regions of gp120. Two panels of sera were used: the first consisted of 109 sera collected from 27 group O- and 92 group M-infected patients in whom the HIV isolates had been genotyped by sequencing or heteroduplex mobility assay. In this panel, the combination of the two assays correctly discriminated 106 samples (100% group O and 96.7% group M samples). The second panel, used for the field evaluation of the two assays, consisted of 157 samples from HIV-1-infected Cameroonian patients, 33 strains having been genotyped. The combination of the two techniques in a serogrouping algorithm discriminated 147 of these samples, 74 being HIV-1 group O and 73 group M. These results always correlated with genotyping results. The 10 sera that were not successfully classified by these assays were from early seroconverters. Altogether, the two assays clearly differentiated 263 of 276 (94.9%) samples in the two panels. On the basis of the genotyping results, the positive predictive value for group discrimination in the two panels was 100% for both GSEIA assays. Our peptide-blocking group-specific EIAs for differentiation and confirmation of HIV-1 group M and group O infection are complementary tools for epidemiological studies and surveillance of HIV-1 group O strain trafficking.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9264285     DOI: 10.1089/aid.1997.13.987

Source DB:  PubMed          Journal:  AIDS Res Hum Retroviruses        ISSN: 0889-2229            Impact factor:   2.205


  5 in total

1.  Immunotyping of human immunodeficiency virus type 1 (HIV): an approach to immunologic classification of HIV.

Authors:  S Zolla-Pazner; M K Gorny; P N Nyambi; T C VanCott; A Nádas
Journal:  J Virol       Date:  1999-05       Impact factor: 5.103

2.  A human immunodeficiency virus prime-boost immunization regimen in humans induces antibodies that show interclade cross-reactivity and neutralize several X4-, R5-, and dualtropic clade B and C primary isolates.

Authors:  F Verrier; S Burda; R Belshe; A M Duliege; J L Excler; M Klein; S Zolla-Pazner
Journal:  J Virol       Date:  2000-11       Impact factor: 5.103

3.  env sequences of simian immunodeficiency viruses from chimpanzees in Cameroon are strongly related to those of human immunodeficiency virus group N from the same geographic area.

Authors:  S Corbet; M C Müller-Trutwin; P Versmisse; S Delarue; A Ayouba; J Lewis; S Brunak; P Martin; F Brun-Vezinet; F Simon; F Barre-Sinoussi; P Mauclere
Journal:  J Virol       Date:  2000-01       Impact factor: 5.103

4.  Rapid assay for simultaneous detection and differentiation of immunoglobulin G antibodies to human immunodeficiency virus type 1 (HIV-1) group M, HIV-1 group O, and HIV-2.

Authors:  A S Vallari; R K Hickman; J R Hackett; C A Brennan; V A Varitek; S G Devare
Journal:  J Clin Microbiol       Date:  1998-12       Impact factor: 5.948

5.  Virus subtype-specific features of natural simian immunodeficiency virus SIVsmm infection in sooty mangabeys.

Authors:  Cristian Apetrei; Rajeev Gautam; Beth Sumpter; Anders C Carter; Thaidra Gaufin; Silvija I Staprans; James Else; Mary Barnes; Robert Cao; Seema Garg; Jeffrey M Milush; Donald L Sodora; Ivona Pandrea; Guido Silvestri
Journal:  J Virol       Date:  2007-05-16       Impact factor: 5.103

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.